These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25036800)

  • 1. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
    Tagde A; Singh H; Kang MH; Reynolds CP
    Blood Cancer J; 2014 Jul; 4(7):e229. PubMed ID: 25036800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
    Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
    Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
    J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B; Keshelava N; Anderson CP; Reynolds CP
    Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
    Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
    Biochem Pharmacol; 1999 Aug; 58(4):655-64. PubMed ID: 10413303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
    Anderson CP; Keshelava N; Satake N; Meek WH; Reynolds CP
    Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
    Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
    Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
    Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
    Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
    Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI
    Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT; Liddil JD; Soble MJ
    Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
    Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX; Ogawa O; Kakehi Y
    Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ; Dorr RT
    Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan.
    Dorr RT
    Biochem Biophys Res Commun; 1987 Apr; 144(1):47-52. PubMed ID: 3579919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.